Taysha Gene Therapies (TSHA) EBT Margin (2023 - 2025)
Taysha Gene Therapies (TSHA) posted EBT Margin of 2099.17% for Q4 2025, up 18.52% sequentially from 2576.33% in Q2 2025, and down 94022.0% YoY from N/an in Q4 2024.
Powered by 
Analysis
Taysha Gene Therapies (TSHA) EBT Margin (2023 - 2025) Analysis & Trends
Taysha Gene Therapies has reported EBT Margin for 3 years, with the latest figure at 2099.17% in Q4 2025.
- Quarterly EBT Margin fell 94022.0% year-over-year to 2099.17% in Q4 2025, while the trailing twelve-month figure through Mar 2026 was 7401.81% (down 554193.0% YoY) and the FY2025 annual result came in at 3326.38%, down 94247.0% from the prior year.
- EBT Margin rose to 2099.17% in Q4 2025 per TSHA's latest filing, from 2576.33% in the prior quarter.
- Over five years, EBT Margin peaked at 434.46% in Q4 2023 and troughed at 2957.21% in Q3 2024.
- A 3-year average of 1605.98% and a median of 1242.14% in 2025 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2024 and 2025: EBT Margin plunged 240863 bps in 2024, then jumped 7250 bps in 2025.
- Over 3 years, EBT Margin stood at 434.46% in 2023, then sank by 167 bps to 1158.95% in 2024, then sank by 81 bps to 2099.17% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 2099.17%, 2576.33%, and 1242.14% for Q4 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Taysha Gene Therapies | 2.06 Bn | 2.06 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -463.85% |
| Jun 30, 2025 | -1,254.33% |
| Mar 31, 2025 | -873.76% |
| Dec 31, 2024 | -902.77% |
| Sep 30, 2024 | -1,331.94% |
| Jun 30, 2024 | -1,788.31% |
| Mar 31, 2024 | -664.50% |
| Dec 31, 2023 | -417.26% |
| Sep 30, 2023 | -350.02% |
| Jun 30, 2023 | -1,027.18% |
| Mar 31, 2023 | -374.29% |